Epstein-Barr Virus and Human Disease

1. Front Matter

   Pages i-xxxi

   PDF

2. Clinical Features of EBV-Associated Diseases

   1. Front Matter

      Pages 1-1

      PDF

   2. Epstein-Barr Virus-Associated Lymphoid and Epithelial Lesions Occurring in the Life Cycle

      • David T. Purtilo

      Pages 3-11

   3. Anti-EBV Titers and the Application of a Prognostic Score to North American Patients with Nasopharyngeal Carcinoma

      • H. Bryan Neel III, William F. Taylor, Gary R. Pearson

      Pages 13-19

   4. Nasopharyngeal Carcinoma in Yugoslavia: Geographical Distribution, Clinical, Pathological and Virological Data

      • S. Stosic, J. Marinkovic, M. Spalajkovic, B. Krejovic, G. de-Thé

      Pages 21-24

   5. A Preliminary Analysis of HLA Studies on Multiple NPC Cases among Siblings from the People’s Republic of China, Hongkong, Singapore and Malaysia

      • B. McKnight, S. T. Lu, L. Ju, N. E. Day, L. Degos, V. Lepage et al.

      Pages 25-29

   6. Prognostic Significance of Serial EBV Antibody Titers in Treated Nasopharyngeal Carcinoma Patients

      • Roger R. Connelly, Paul H. Levine, Gregory Milman

      Pages 31-37

   7. EBV-Associated Antibodies and Other Antibodies in Nasopharyngeal Cancer Patients before and after Radiotherapy

      • T. C. Lynn, J. H. Wang, C. L. Kao, S. C. Huang, S. M. Tu

      Pages 39-41

   8. IgA/EA: Prognosis Marker for Relapse among NPC Patients with Complete Remission after Radiotherapy

      • G. de-The, F. de Vathaire, H. Sancho-Garnier, H. de-The, G. Schwaab, C. Micheau et al.

      Pages 43-45

   9. Epstein-Barr Virus Infection in Families with a Childhood Index Case of Infectious Mononucleosis

      • Ciro V. Sumaya, Yasmin Ench

      Pages 47-48

   10. Antibodies to EBV Specific Enzymes in the Chronic EBV Syndrome

       • James F. Jones, Marshall Williams, Robert T. Schooley, Ronald Glaser

       Pages 49-52

   11. Presence of Monoclonal and Oligoclonal B-Cell Proliferation in Fatal Infectious Mononucleosis

       • Beda Brichacek, Jack Davis, David T. Purtilo

       Pages 53-54

   12. Comparison of EBV Serological Reactivities between Two Groups of NPC Patients Surviving More Than 7 Years or Dead 2 Years after Diagnosis

       • C. Desgranges, V. U. Nguyen, S. Souche, R. Ellouz, G. de-Thé

       Pages 55-57

   13. Application of EBV-Serology to the Clinical Monitoring of Patients with Nasopharyngeal Carcinoma

       • M. Yadav, N. Malliga, M. K. Tan, D. V. Ablashi

       Pages 59-61

   14. A Prospective Study of Antibodies to Epstein-Barr Virus DNase and Viral Capsid Antigen (IgA) in the Prognosis of Nasopharyngeal Carcinoma

       • Mow-Ming Hsu, Jen-Yang Chen, Chien-Jen Chen

       Pages 63-65

   15. Anti-EBV DNase Antibody as a Marker for Prospective Study of Nasopharyngeal Carcinoma

       • C. S. Yang, J. Y. Chen, M. Y. Liu, C. J. Chen, M. M. Hsu, T. C. Lynn et al.

       Pages 67-69

   16. HLA -A, -B and -DR Antigens in North African Patients with Nasopharyngeal Carcinoma

       • F. de Vathaire, P. Herait, M. Lipinski, H. Sancho-Garnier, G. de Thé, T. Tursz

       Pages 71-72

   17. Autoantibodies Against the Epstein-Barr Virus Receptor (EBVR) in Sera from Rheumatoid Arthritis Patients

       • Raymond Frade, Alice Kahan, Christiane Charriaut-Marlangue, André Kahan, Monique Barel

       Pages 73-75

3. New Developments in Clinical Studies of EBV-Associated Diseases

   1. Front Matter

      Pages 77-77

      PDF

   2. Evidence for Association of Epstein-Barr Virus with Malignant Lymphoepithelial Lesion of Salivary Gland

      • S. Clift, A. Lanier, K. Kline, W. Henle, G. Henle, N. Raab-Traub

      Pages 79-83

Since its discovery as the cause of infectious mononucleosis in 1964, the Epstein-Barr virus (EBV) has been etiologically implicated in an increasing number of human diseases. Generally considered the first human oncogenic virus because of a number of studies linking it with Burkitt's lymphoma and nasopharyngeal carcinoma (NPC), as well as its documented oncogenicity in nonhuman primates, EBVhas served as a model for identifying subsequent candidate oncogenic viruses and the stimulus for Evans' revision of the Henle-Koch postulates to accommodate the problems in proving viral oncogenicity in humans. Research on the role of EBV in human cancer was particularly en­ hanced (a) by the pioneering work of Werner and Gertrude Henle, and (b) by the coordinated efforts of the Special Virus Leukemia Program and its successors, the Special Virus Cancer Program and the Virus Cancer Program of the National Cancer Institute (NCI). Initiated by Dr. Frank J. Rauscher, who subsequently became director of the Ncr and is now Vice-President of the American Cancer Society, and expanded by Dr. John B. Moloney, whose contributions to cancer research were honored at this Second International Symposium on EBV and Associated Malignant Diseases, these NCI contract-sup­ ported programs brought together investigators from all over the world to participate in a joint effort to unravel the mystery of EBV behavior and pathogenicity. It was these programs that gave us the opportunity to work with such outstanding people as Professor Yohei Ito, to whom this book is dedicated.

• AIDS
• Antigen
• blood
• diseases
• infection
• infections
• interferon
• leukemia
• lymphocytes
• phenotype
• proteins
• regulation
• transplantation
• vaccine
• virus

• National Cancer Institute, Bethesda, USA

  P. H. Levine, D. V. Ablashi

• Showa University Research Institute, St. Petersburg, USA

  M. Nonoyama

• Georgetown University Medical Center, USA

  G. R. Pearson

• The Ohio State University, Columbus, USA

  R. Glaser

Policies and ethics